GSK announces updated, longer-term results from phase 2 study of Jemperli

GSK plc announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli as a first-line treatment-as an alternative to surgery-for mismatch repair deficient, or dMMR, locally advanced rectal cancer. “The trial showed an unprecedented 100% clinical complete response rate – cCR – in 42 patients who completed treatment with dostarlimab, defined as complete pathologic response or no evidence of tumours as assessed by magnetic resonance imaging, endoscopy and digital rectal exam. In the first 24 patients evaluated, a sustained clinical complete response with a median follow-up of 26.3 months was observed,” the company stated. These late-breaking data are being presented today at the 2024 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago, IL as a rapid oral presentation. The latest research presented today from the phase II trial builds on the findings initially presented in a late-breaking presentation at the 2022 ASCO Annual Meeting with simultaneous publication in The New England Journal of Medicine. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The data showing no evidence of disease in 42 patients is remarkable. These results bring us one step closer to understanding the potential of dostarlimab in this curative-intent setting for patients with dMMR locally advanced rectal cancer. We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.”